Skip to main content
OpenTrials

Clinical trial condition

Lymphoma, B-Cell, Marginal Zone

Explore clinical trials studying Lymphoma, B-Cell, Marginal Zone. Study availability and eligibility vary by location and protocol.

647 public trials 86 recruiting studies
Refine in advanced search Browse all conditions

Lymphoma, B-Cell, Marginal Zone trial results

Active, not recruiting

Lenalidomide and Ibrutinib in Treating Patients With Relapsed or Refractory B-Cell Non-Hodgkin Lymphoma

NCT01955499

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +21 more
Locations
  • University of Chicago Comprehensive Cancer Center Chicago, Illinois, United States
  • Ohio State University Comprehensive Cancer Center Columbus, Ohio, United States
  • University Health Network-Princess Margaret Hospital Toronto, Ontario, Canada
View Trial Details
Active, not recruiting

Copanlisib and Rituximab in Marginal Zone Lymphoma Patients

NCT03474744

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Med. Uni Wien AKH, Klinische Abteilung für Onkologie, Innere Medizin I Vienna, Austria
  • St. Josef-Hospital, Medizinische Klinik I Bochum, Germany
  • Johanniter GmbH, Johanniter-Krankenhaus Bonn, Germany
  • ÜBAG MVZ Dr. Vehling-Kaiser GmbH Dingolfing Dingolfing, Germany
View all 18 locations
View Trial Details
Active, not recruiting

Obinutuzumab in Marginal Zone Lymphoma

NCT03322865

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • Augusta-Kranken-Anstalt gGmbH Bochum, Germany
  • University Hospital Essen Essen, Germany
  • Universitätsklinikum Freiburg Freiburg im Breisgau, Germany
  • Universitätsmedizin Georg-August-University Göttingen, Germany
View Trial Details
Active, not recruiting

Long-term Follow-up Study of Allogeneic Gamma Delta (γδ) CAR T Cells

NCT04911478

Conditions
Diffuse Large B Cell Lymphoma, Hemic and Lymphatic Diseases, Immune System Diseases, +14 more
Locations
  • Blood and Marrow Transplant Program Palo Alto, California, United States
  • Norton Cancer Institute Louisville, Kentucky, United States
  • Baylor Scott & White Research Institute Dallas, Texas, United States
  • MD Anderson Caner Center Houston, Texas, United States
View Trial Details
Active, not recruiting

MALIBU Trial - Combination of Ibrutinib and Rituximab in Untreated Marginal Zone Lymphomas

NCT03697512

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +11 more
Locations
  • CHU UCL Namur / site Godinne Yvoir, Belgium
  • CHU de Tours - Hôpital Bretonneau Tours, Cedex 01, France
  • CHU de Montpellier Montpellier, Cedex 05, France
  • CHU d'Estaing Clermont-Ferrand, Cedex 1, France
View all 36 locations
View Trial Details
Active, not recruiting

Study of Acalabrutinib and Tafasitamab in MZL Patients

NCT04646395

Conditions
Hemic and Lymphatic Diseases, Immune System Diseases, Immunoproliferative Disorders, +9 more
Locations
  • University of Wien Vienna, Austria
  • ASST Spedali Civili di Brescia Brescia, Italy
  • Fondazione IRCCS - Istituto Nazionale dei Tumori Milan, Italy
  • Fondazione IRCCS Cà Granda-Ospedale Maggiore Policlinico Milan, Italy
View Trial Details

Related conditions